VolitionRx Limited – AMEX:VNRX

Add to watchlist

$0.67

+0.05

+8.94%

Market closed

Open in 3 days

-6.66%

month

-6.66%

quarter

-13.19%

year

Market Cap	59.86M
Enterprise value	87.09M

P/E	-3.29
EV/Sales	189.19
EV/EBITDA	-1.94
Price/Sales	201.99
Price/Book	-36.11
PEG ratio	N/A
EPS	-0.46

Revenue	797.02K
EBITDA	-33.85M
Income	-34.90M
Revenue Q/Q	14.50%
Revenue Y/Y	133.05%

Profit margin	-9895.09%
Oper. margin	-5163.28%
Gross margin	8.64%
EBIT margin	-5163.28%
EBITDA margin	-4247.12%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

VolitionRx Limited (AMEX:VNRX): Profit margin
Jun 2023	216.31K	-9.47M	-4378.43%
Sep 2023	165.21K	-8.37M	-5066.43%
Dec 2023	243.97K	-8.69M	-3565.25%
Mar 2024	171.53K	-8.36M	-4877.95%

VolitionRx Limited Financials Estimate

Q Y

VolitionRx Limited (AMEX:VNRX): Analyst Estimates
Sep 2025	2.3M	-4.87M	-211.75%
Oct 2025	2.2M	-4.91M	-223.52%
Dec 2025	5.17M	0
Dec 2025	2.8M	-4.09M	-146.35%

Analysts Price target
Financials & Ratios estimates

VolitionRx Limited (AMEX:VNRX): Debt to assets
Jun 2023	27560914	22.44M	81.43%
Sep 2023	18040868	20.89M	115.8%
Dec 2023	27950498	36.24M	129.66%
Mar 2024	19434900	35.64M	183.39%

VolitionRx Limited (AMEX:VNRX): Cash Flow
Jun 2023	-7.34M	-301.39K	17.34M
Sep 2023	-8.41M	-273.04K	-274.75K
Dec 2023	6.37M	-307.12K	3.77M
Mar 2024	-8.34M	-78.80K	-209.39K

VolitionRx Limited alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

VolitionRx Limited (AMEX:VNRX): Employee count
Aug 2023	104
Sep 2023	111
Oct 2023	111
Nov 2023	111
Dec 2023	114
Jan 2024	114
Feb 2024	114
Mar 2024	110
Apr 2024	110
May 2024	110
Jun 2024	108
Jul 2024	108

VolitionRx Limited
Hedge Funds Holdings Q2 2022

33.04% -0.60%

of VNRX is owned by hedge funds

30 -1

hedge funds hold VNRX stock

5.96M -108.15K

shares is hold by hedge funds

VNRX hedge funds holdings changes

VolitionRx Limited
Insider Trading

VolitionRx Limited (AMEX:VNRX): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	20000
Aug 2024	150000	0
Dec 2024	445648	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	9 Dec 2024	INNES GUY ARCHIBALD director director	Common Stock	174,764	$0.57	$99,965
Purchase	9 Dec 2024	STILL TIMOTHY I director director	Common Stock	87,382	$0.57	$49,983
Purchase	9 Dec 2024	MICALLEF JACOB VINCENT officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	43,691	$0.57	$24,991
Purchase	9 Dec 2024	REYNOLDS CAMERON JOHN director, officer: President and CEO director, officer: President an..	Common Stock	139,811	$0.57	$79,972
Purchase	20 Aug 2024	INNES GUY ARCHIBALD director director	Common Stock	150,000	$0.67	$100,500
Sale	2 Jan 2024	EIGHT CORP LTD 10 percent owner 10 percent owner	VOLITIONRX LTD	20,000	$0.9	$18,000
Purchase	18 Dec 2023	BUTERA SALVATORE THOMAS officer: CEO - Volition Veterinary officer: CEO - Volition Veterin..	Common Stock	10,000	$0.83	$8,300
Sale	15 Dec 2023	EIGHT CORP LTD 10 percent owner 10 percent owner	Common Stock	20,000	$0.75	$15,000
Purchase	15 Dec 2023	BUTERA SALVATORE THOMAS officer: CEO - Volition Veterinary officer: CEO - Volition Veterin..	Common Stock	10,000	$0.77	$7,700
Purchase	13 Dec 2023	ROOTSAERT RODNEY GERARD officer: Secretary officer: Secretary	Common Stock	10,000	$0.6	$6,000

VNRX insider trading transactions

VolitionRx Limited
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 14 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 26 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 15 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 15 Aug 2023	Q2 2023 Earnings Call Transcript

VNRX earnings call transcripts

VolitionRx Limited
Latest News

Thursday, 12 December 2024
08:00	VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants	prnewswire.com
Tuesday, 10 December 2024
08:00	Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening	prnewswire.com
Friday, 6 December 2024
09:00	VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering	prnewswire.com
Friday, 15 November 2024
11:47	VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript	seekingalpha.com
Thursday, 14 November 2024
16:10	VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update	prnewswire.com
Friday, 8 November 2024
08:00	VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update	prnewswire.com
Wednesday, 6 November 2024
16:10	Volition Appoints Timothy I. Still as Chairman	prnewswire.com
Thursday, 31 October 2024
08:00	Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating	prnewswire.com
Wednesday, 9 October 2024
08:00	Volition to share new 'NETs in sepsis management' data insights at upcoming webinar	prnewswire.com
Thursday, 3 October 2024
08:00	Volition hosts NETs in sepsis management symposium at ESICM Lives 2024	prnewswire.com
Monday, 30 September 2024
16:10	Volition Appoints Dr. Ethel Rubin as an Independent Director	prnewswire.com
Wednesday, 11 September 2024
08:00	Volition Hosts KOL Roundtable on Sepsis	prnewswire.com
Thursday, 15 August 2024
12:11	VolitionRx Limited (VNRX) Q2 2024 Earnings Call Transcript	seekingalpha.com
Wednesday, 14 August 2024
16:10	VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update	prnewswire.com
Friday, 9 August 2024
08:00	VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering	prnewswire.com
Tuesday, 6 August 2024
08:00	VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update	prnewswire.com
Tuesday, 9 July 2024
08:30	Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensing	prnewswire.com
Thursday, 27 June 2024
08:00	VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting	prnewswire.com
Wednesday, 29 May 2024
08:00	VolitionRx Limited to Present at Jefferies Global Healthcare Conference	prnewswire.com
Tuesday, 14 May 2024
20:24	VolitionRx Limited (VNRX) Q1 2024 Earnings Call Transcript	seekingalpha.com
Monday, 13 May 2024
16:10	VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update	prnewswire.com
Wednesday, 8 May 2024
08:00	VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update	prnewswire.com
Tuesday, 23 April 2024
08:00	Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech	prnewswire.com
Tuesday, 26 March 2024
12:43	VolitionRx Limited (VNRX) Q4 2023 Earnings Call Transcript	seekingalpha.com
Monday, 25 March 2024
16:10	VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update	prnewswire.com
Thursday, 21 March 2024
08:30	VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update	prnewswire.com
Wednesday, 20 March 2024
08:30	Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan	prnewswire.com
Tuesday, 19 March 2024
16:30	Volition appoints Dr Andrew Retter as Chief Medical Officer	prnewswire.com
Friday, 2 February 2024
08:00	Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar	prnewswire.com
Thursday, 18 January 2024
04:54	Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances	InvestorPlace

Frequently Asked Questions (FAQ)

What's the price of VolitionRx Limited stock today?

One share of VolitionRx Limited stock can currently be purchased for approximately $0.67.
When is VolitionRx Limited's next earnings date?

Unfortunately, VolitionRx Limited's (VNRX) next earnings date is currently unknown.
Does VolitionRx Limited pay dividends?

No, VolitionRx Limited does not pay dividends.
How much money does VolitionRx Limited make?

VolitionRx Limited has a market capitalization of 59.86M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 153.04% to 775.3K US dollars.
What is VolitionRx Limited's stock symbol?

VolitionRx Limited is traded on the AMEX under the ticker symbol "VNRX".
What is VolitionRx Limited's primary industry?

Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
How do i buy shares of VolitionRx Limited?

Shares of VolitionRx Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does VolitionRx Limited have?

As Jul 2024, VolitionRx Limited employs 108 workers, which is 2% less then previous quarter.
When VolitionRx Limited went public?

VolitionRx Limited is publicly traded company for more then 13 years since IPO on 2 Mar 2012.
What is VolitionRx Limited's official website?

The official website for VolitionRx Limited is volition.com.
Where are VolitionRx Limited's headquarters?

VolitionRx Limited is headquartered at 13215 Bee Cave Parkway, Austin, TX.
How can i contact VolitionRx Limited?

VolitionRx Limited's mailing address is 13215 Bee Cave Parkway, Austin, TX and company can be reached via phone at +64 6 650 1351.

VolitionRx Limited

volition.com

Exchange:

AMEX

Full time employees:

101

Industry:

Medical - Diagnostics & Research

Sector:

Healthcare

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

+64 6 650 1351

13215 Bee Cave Parkway
Austin, TX 78738

CIK: 0000093314
ISIN: US9286611077
CUSIP: 928661107